DK2696757T3 - Fremgangsmåde til bestemmelse af den metaboliske kapacitet af mindst ét enzym - Google Patents
Fremgangsmåde til bestemmelse af den metaboliske kapacitet af mindst ét enzym Download PDFInfo
- Publication number
- DK2696757T3 DK2696757T3 DK12720448.5T DK12720448T DK2696757T3 DK 2696757 T3 DK2696757 T3 DK 2696757T3 DK 12720448 T DK12720448 T DK 12720448T DK 2696757 T3 DK2696757 T3 DK 2696757T3
- Authority
- DK
- Denmark
- Prior art keywords
- function
- product
- individual
- substrate
- expresses
- Prior art date
Links
- 230000002503 metabolic effect Effects 0.000 title claims description 46
- 102000004190 Enzymes Human genes 0.000 title claims description 41
- 108090000790 Enzymes Proteins 0.000 title claims description 41
- 238000000034 method Methods 0.000 title claims description 40
- 239000000758 substrate Substances 0.000 claims description 83
- 230000037396 body weight Effects 0.000 claims description 17
- 238000009826 distribution Methods 0.000 claims description 9
- 230000005484 gravity Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 230000000284 resting effect Effects 0.000 claims description 5
- 238000012937 correction Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 238000012895 mono-exponential function Methods 0.000 claims description 2
- 230000006870 function Effects 0.000 description 81
- 230000004060 metabolic process Effects 0.000 description 32
- XVAIDCNLVLTVFM-UHFFFAOYSA-N methacetin Chemical compound COC1=CC=C(NC(C)=O)C=C1 XVAIDCNLVLTVFM-UHFFFAOYSA-N 0.000 description 24
- 210000004185 liver Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 238000005259 measurement Methods 0.000 description 11
- 230000029058 respiratory gaseous exchange Effects 0.000 description 11
- 238000002591 computed tomography Methods 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000009021 linear effect Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 239000002539 nanocarrier Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000004566 IR spectroscopy Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 230000007102 metabolic function Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- PPGXDBJURPEKDZ-UHFFFAOYSA-N 3-ethoxychromen-2-one Chemical compound C1=CC=C2OC(=O)C(OCC)=CC2=C1 PPGXDBJURPEKDZ-UHFFFAOYSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241001523405 Limax Species 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009022 nonlinear effect Effects 0.000 description 1
- 239000003415 peat Substances 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000000207 volumetry Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/083—Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
- A61B5/0836—Measuring rate of CO2 production
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/0813—Measurement of pulmonary parameters by tracers, e.g. radioactive tracers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/087—Measuring breath flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/097—Devices for facilitating collection of breath or for directing breath into or through measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
- G01J3/42—Absorption spectrometry; Double beam spectrometry; Flicker spectrometry; Reflection spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/46—NMR spectroscopy
- G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01T—MEASUREMENT OF NUCLEAR OR X-RADIATION
- G01T1/00—Measuring X-radiation, gamma radiation, corpuscular radiation, or cosmic radiation
- G01T1/29—Measurement performed on radiation beams, e.g. position or section of the beam; Measurement of spatial distribution of radiation
- G01T1/2914—Measurement of spatial distribution of radiation
- G01T1/2985—In depth localisation, e.g. using positron emitters; Tomographic imaging (longitudinal and transverse section imaging; apparatus for radiation diagnosis sequentially in different planes, steroscopic radiation diagnosis)
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/26—Mass spectrometers or separator tubes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Physics & Mathematics (AREA)
- High Energy & Nuclear Physics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Claims (10)
1. Fremgangsmåde til bestemmelse af den metaboliske kapacitet af mindst ét enzym, omfattende de følgende trin: • tidsopløst bestemmelse af koncentrationen af et produkt i udåndingsluften fra et individ, hvor produktet er dannet ved metabolisering af et til individet tidligere indgivet substrat, ved hjælp af mindst ét enzym i individet, • tilpasning af en modelfunktion til de målte værdier af produktkoncentrationen, som opnås gennem den tidsopløste bestemmelse af produktkoncentrationen, og • bestemmelse af den metaboliske kapacitet af enzymet på basis af parametre i modelfunktionen, som specificerer modelfunktionen, kendetegnet ved, at produktkoncentrationen ikke bestemmes, før den maksimale produktkoncentration i individets udåndingsluft er nået, og ved, at bestemmelse af enzymets metaboliske kapacitet sker på basis af mindst to parametre i modelfunktionen under den forudsætning, at maksimumværdien af modelfunktionen og tidskonstanten af modelfunktionen ikke vælges som parametre samtidigt, for så vidt at modelfunktionen er en mono-eksponentiel funktion, og under den yderligere forudsætning, at et starttidspunkt og/eller et sluttidspunkt af modelfunktionen ikke vælges som parametre.
2. Fremgangsmåde ifølge krav 1, kendetegnet ved, at parametrene vælges fra gruppen indeholdende maksimumværdien af modelfunktionen, det i’te moment i modelfunktionen med i = 1, 2, 3, 4,...., det j’te centrale moment af modelfunktionen med j = 1, 2, 3, 4,...., standardafvigelsen af modelfunktionen, en tidskonstant af modelfunktionen, tyngdepunktet af tidskonstanterne, middelafvigelsen af tidskonstanterne fra tyngdepunktet, variationen af tidskonstanterne, fordelingen af tidskonstanterne, vægtningen af tidskonstanterne, vægtningen af fordelingen af tidskonstanterne, vægtningen af variationen af tidskonstanterne.
3. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at bestemmelsen af produktkoncentrationen sker under gennemstrømning, således at udåndingsluften strømmer gennem et måleapparat, der anvendes til bestemmelse af koncentrationen, hvorved en strømningshastighed af udåndingsluften bestemmes.
4. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at den samlede udåndingsluft i mindst ét åndedræt i individet anvendes som udåndingsluft.
5. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at bestemmelse af produktkoncentrationen sker, mens individet befinder sig i det væsentlige i en hvileposition.
6. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at bestemmelse af produktkoncentrationen sker, mens individet befinder sig i en liggende eller siddende position, hvori positionen af benene og/eller overkroppen af individet ændres mindre end 45 grader, især mindre end 30 grader og især mindre end 15 grader sammenlignet med en forudbestemt position.
7. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at modelfunktionen kan udtrykkes ved den følgende ligning: MetPow = cal* [F(produkt,t)-f(produkt,t)nat]*g(P)*h(n)*L(n/M)*(n/M2)*V(n/M) hvori MetPow betegner den metaboliske kapacitet, cal er en konstant, som tager hensyn til korrektioner, F(produkt,t) er en funktion, der udtrykker dynamikken af udåndet produkt, f(produkt,t)nat er en funktion, der udtrykker den naturlige tæthed af produktet i den af individet udåndede luft før substratindgivelse, g(P) er en funktion, som udtrykker individets produktproduktionshastighed P’s afhængighed af individets aktivitetsstatus, h(n) er en funktion, der udtrykker det genererede antal produktmolekyler per substratmolekyle. L(n/M) er en funktion, der udtrykker et ikke-lineært forløb af den metaboliske kapacitet i afhængighed af antallet af indgivne substratmolekyler n, hvor M angiver individets kropsvægt, og V(n/M) er en funktion, der udtrykker afhængigheder som følge af forskellige procedurer til indgivelse af substratet.
8. Fremgangsmåde ifølge krav 7, kendetegnet ved, at g(P) = P og/eller h(n) = 1 og/eller V(n/M) = 1.
9. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at modelfunktionen kan udtrykkes ved den følgende ligning: MetPow = cal* [F(13C02,12C02,t)-f(13C02j2C02,t)nat]Wco2)*h(n)*L(n/M)*(n/M2) *V(n/M), hvori MetPow betegner den metaboliske kapacitet, cal er en konstant, som tager hensyn til korrektionerne, F(13C02,12C02,t) er en funktion, der udtrykker dynamikken af udåndet 13C02 som produkt eller udtrykker dynamikken af udåndet forhold mellem 13C02/12C02, f(13C02,12C02,t)nat er en funktion, der udtrykker den naturlige tæthed af 13C02 og 12C02 i den af individet udåndede luft før indgivelse af substrat, g(PC02) er en funktion, som udtrykker individets C02- produktproduktionshastighed Peck’s afhængighed af individets aktivitetsstatus, h(n) er en funktion, der udtrykker det genererede antal CO2- produktmolekyler per substratmolekyle. L(n/M) er en funktion, der udtrykker et ikke-lineært forløb af den metaboliske kapacitet i afhængighed af antallet af indgivne substratmolekyler n, hvor M angiver individets kropsvægt, og V(n/M) er en funktion, der udtrykker afhængigheder som følge af forskellige procedurer til indgivelse af substratet.
10. Fremgangsmåde ifølge krav 9, kendetegnet ved, at g(PC02) = Pco2 og/eller h(n) = 1 og/eller V(n/M) = 1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011007310A DE102011007310A1 (de) | 2011-04-13 | 2011-04-13 | Verfahren zur Bestimmung der metabolischen Leistung mindestens eines Enzyms |
| US201161476113P | 2011-04-15 | 2011-04-15 | |
| PCT/EP2012/056808 WO2012140213A2 (en) | 2011-04-13 | 2012-04-13 | Method for determining the metabolic capacity of at least one enzyme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2696757T3 true DK2696757T3 (da) | 2016-12-05 |
Family
ID=46935325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12720448.5T DK2696757T3 (da) | 2011-04-13 | 2012-04-13 | Fremgangsmåde til bestemmelse af den metaboliske kapacitet af mindst ét enzym |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9560989B2 (da) |
| EP (1) | EP2696757B1 (da) |
| JP (1) | JP6092845B2 (da) |
| CN (1) | CN103547215B (da) |
| AU (1) | AU2012241802B2 (da) |
| BR (1) | BR112013026380B1 (da) |
| CA (1) | CA2832940C (da) |
| DE (1) | DE102011007310A1 (da) |
| DK (1) | DK2696757T3 (da) |
| EA (1) | EA028154B1 (da) |
| ES (1) | ES2593797T3 (da) |
| PT (1) | PT2696757T (da) |
| WO (1) | WO2012140213A2 (da) |
| ZA (1) | ZA201308470B (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102014014671B3 (de) * | 2014-10-04 | 2015-12-10 | Fischer Analysen Instrumente Gmbh | 13C-Atemgas-Test zur Überprüfung der Magen-/Darm-Funktion und/oder Stoffwechselfunktionen und Vorrichtung hierfür |
| US11103158B2 (en) | 2015-09-14 | 2021-08-31 | Freie Universität Berlin | Pure non-invasive method for identification of organ diseases or impaired organ function by investigation of marker substances in exhaled air stimulated by inhaled marker substances |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1596182A3 (en) | 1995-10-09 | 2008-02-20 | Otsuka Pharmaceutical Company, Limited | Method for spectrometrically measuring isotopic gas and apparatus thereof |
| EP1478407A1 (en) * | 2002-02-27 | 2004-11-24 | Cambridge Isotope Laboratories, Inc. | Use of 13c labelled substance for measuring lung function |
| US7343917B2 (en) * | 2003-09-22 | 2008-03-18 | Resmed Limited | Clear cycle for ventilation device |
| EP1845840B1 (en) * | 2005-01-26 | 2018-05-30 | The Regents of the University of Colorado | Methods for diagnosis and intervention of hepatic disorders |
| CN101163791A (zh) | 2005-04-16 | 2008-04-16 | 大塚制药株式会社 | 使用呼吸检测来评定细胞色素p450 2d6同工酶活性的方法和组合物 |
| EP2821788A1 (de) * | 2005-06-25 | 2015-01-07 | Freie Universität Berlin | Analyseverfahren zur Bestimmung eines Organfunktionsparameters |
| US8512258B2 (en) | 2005-11-11 | 2013-08-20 | Exalenz Bioscience Ltd. | Breath test device and method |
| WO2007054940A2 (en) | 2005-11-11 | 2007-05-18 | Breathid (2006) | Breath test device and method |
| KR100718208B1 (ko) | 2006-04-21 | 2007-05-15 | 한국과학기술원 | Ｃｒｄ 및 ｓｒｄ를 이용한 대사흐름 분석방법 |
-
2011
- 2011-04-13 DE DE102011007310A patent/DE102011007310A1/de not_active Withdrawn
-
2012
- 2012-04-13 CA CA2832940A patent/CA2832940C/en not_active Expired - Fee Related
- 2012-04-13 AU AU2012241802A patent/AU2012241802B2/en not_active Ceased
- 2012-04-13 CN CN201280024565.2A patent/CN103547215B/zh not_active Expired - Fee Related
- 2012-04-13 BR BR112013026380-6A patent/BR112013026380B1/pt not_active IP Right Cessation
- 2012-04-13 DK DK12720448.5T patent/DK2696757T3/da active
- 2012-04-13 US US14/111,165 patent/US9560989B2/en active Active
- 2012-04-13 JP JP2014504344A patent/JP6092845B2/ja not_active Expired - Fee Related
- 2012-04-13 EA EA201301153A patent/EA028154B1/ru not_active IP Right Cessation
- 2012-04-13 PT PT127204485T patent/PT2696757T/pt unknown
- 2012-04-13 EP EP12720448.5A patent/EP2696757B1/en active Active
- 2012-04-13 WO PCT/EP2012/056808 patent/WO2012140213A2/en active Application Filing
- 2012-04-13 ES ES12720448.5T patent/ES2593797T3/es active Active
-
2013
- 2013-11-11 ZA ZA2013/08470A patent/ZA201308470B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103547215A (zh) | 2014-01-29 |
| ES2593797T3 (es) | 2016-12-13 |
| AU2012241802A1 (en) | 2013-10-31 |
| WO2012140213A2 (en) | 2012-10-18 |
| EP2696757B1 (en) | 2016-08-10 |
| CA2832940A1 (en) | 2012-10-18 |
| EA201301153A1 (ru) | 2014-02-28 |
| JP6092845B2 (ja) | 2017-03-08 |
| EP2696757A2 (en) | 2014-02-19 |
| US9560989B2 (en) | 2017-02-07 |
| ZA201308470B (en) | 2014-08-27 |
| CN103547215B (zh) | 2015-12-02 |
| EA028154B1 (ru) | 2017-10-31 |
| JP2014518518A (ja) | 2014-07-31 |
| US20140107516A1 (en) | 2014-04-17 |
| AU2012241802B2 (en) | 2016-06-30 |
| BR112013026380B1 (pt) | 2021-08-24 |
| WO2012140213A3 (en) | 2013-01-31 |
| CA2832940C (en) | 2019-07-02 |
| DE102011007310A1 (de) | 2012-10-18 |
| BR112013026380A2 (pt) | 2016-12-27 |
| PT2696757T (pt) | 2016-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zavorsky et al. | Standardisation and application of the single-breath determination of nitric oxide uptake in the lung | |
| Perez-Suarez et al. | Accuracy and precision of the COSMED K5 portable analyser | |
| Sukul et al. | FEV manoeuvre induced changes in breath VOC compositions: an unconventional view on lung function tests | |
| Minh et al. | Noninvasive measurement of plasma glucose from exhaled breath in healthy and type 1 diabetic subjects | |
| Harris et al. | Cerebral blood flow response to acute hypoxic hypoxia | |
| Dummer et al. | Accurate, reproducible measurement of acetone concentration in breath using selected ion flow tube-mass spectrometry | |
| Albrecht et al. | Influence of the respirator on volatile organic compounds: an animal study in rats over 24 hours | |
| Rosdahl et al. | The Moxus Modular metabolic system evaluated with two sensors for ventilation against the Douglas bag method | |
| DK2696757T3 (da) | Fremgangsmåde til bestemmelse af den metaboliske kapacitet af mindst ét enzym | |
| Szabó et al. | Volatile sulphur compound measurement with OralChromaTM: a methodological improvement | |
| US9999756B2 (en) | System for delivery of gaseous imaging contrast agents and methods for using same | |
| WO2006043674A1 (ja) | Ｐｅｔ撮像による画像定量化装置及び方法 | |
| Slingers et al. | Real-time selected ion flow tube mass spectrometry to assess short-and long-term variability in oral and nasal breath | |
| Anderson et al. | Impact of airway gas exchange on the multiple inert gas elimination technique: theory | |
| US20110313677A1 (en) | Method for determining the liver performance of a living organism by the means of quantitative measuring the metabolization of substrates | |
| Sukul et al. | Physio-Metabolic Monitoring via Breath Employing Real-Time Mass Spectrometry: Importance, Challenges, Potentials, and Pitfalls | |
| Debnath et al. | An Overview on Pharmacokinetics and Pharmacokinetic Modeling | |
| Bastide et al. | Handheld device quantifies breath acetone for real-life metabolic health monitoring | |
| Ralston et al. | Measured oxygen consumption during pediatric cardiac catheterization is more accurate than assumed oxygen consumption | |
| Ravasi et al. | Imaging of the muscarinic acetylcholine neuroreceptor in rats with the M2 selective agonist [18F] FP-TZTP | |
| Depledge et al. | A technique for measuring carbon monoxide uptake in mice | |
| King et al. | Interplay Between Volatile Biomarkers and Body Fluids | |
| Muradyan et al. | Hyperpolarized 129 Xenon MRI of the Lung | |
| Bastide et al. | Sensors & Diagnostics | |
| Miekisch et al. | Diagnostic potential of breath analysis–focus on the dynamics of volatile organic compounds |